Who are Egrifta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taxotere, Geref.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tesamorelin-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Egrifta — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Egrifta (TESAMORELIN ACETATE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth Hormone Releasing Factor Analog. Area: Immunology.

marketed Growth Hormone Releasing Factor Analog Growth hormone-releasing hormone receptor Immunology Recombinant protein Live · refreshed every 30 min

Target snapshot

Egrifta (TESAMORELIN ACETATE) — Theratechnologies. Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Egrifta TARGET	TESAMORELIN ACETATE	Theratechnologies	marketed	Growth Hormone Releasing Factor Analog	Growth hormone-releasing hormone receptor	2010-01-01
Taxotere	Docetaxel	Sanofi	marketed	Microtubule Inhibitor [EPC]	Growth hormone-releasing hormone receptor	1996-01-01
Geref	sermorelin		marketed	sermorelin	Growth hormone-releasing hormone receptor	1990-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-08-07 — Taxotere · 10842770 · Formulation · US
2033-09-30 — Taxotere · 9308195 · Formulation · US
2033-09-30 — Taxotere · 9763880 · Method of Use · US
2033-09-30 — Taxotere · 8940786 · Formulation · US
2036-03-14 — Taxotere · 10398785 · Formulation · US
2036-05-16 — Taxotere · 12090135 · Formulation · US
2036-05-16 — Taxotere · 11419842 · Formulation · US
2036-05-16 — Taxotere · 12090134 · Formulation · US

Sponsor landscape (Growth Hormone Releasing Factor Analog class)

Theratechnologies · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Egrifta — Competitive Intelligence Brief. https://druglandscape.com/ci/tesamorelin-acetate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing